Fig. 4From: Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancerComparison of the rate of GCN alteration obtained by in situ hybridization methods and array-based platform: a EGFR, b HER2, c c-MYC, and d METBack to article page